There Is Still Room For Arrowhead Pharmaceuticals Inc. (ARWR) to Improve Its Value – Let’s Wait for Clarity

The price of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $27.89 in the last session, up 2.50% from day before closing price of $27.21. In other words, the price has increased by $+0.68 from its previous closing price. On the day, 517415 shares were traded.

Ratios:

We take a closer look at ARWR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 2.45 whereas as Long-Term Debt/Eq ratio is at 2.42.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 04, 2023, initiated with a Buy rating and assigned the stock a target price of $29.

On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 20 ’24 when Lu Hongbo bought 1,000 shares for $27.50 per share. The transaction valued at 27,500 led to the insider holds 33,680 shares of the business.

Lu Hongbo bought 1,000 shares of ARWR for $28,000 on Mar 19 ’24. The Director now owns 32,680 shares after completing the transaction at $28.00 per share. On Mar 18 ’24, another insider, Lu Hongbo, who serves as the Director of the company, bought 1,000 shares for $27.49 each. As a result, the insider paid 27,490 and bolstered with 31,680 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3.37B and an Enterprise Value of 3.27B. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.01 while its Price-to-Book (P/B) ratio in mrq is 18.69. Its current Enterprise Value per Revenue stands at 17.97 whereas that against EBITDA is -12.16.

Stock Price History:

Over the past 52 weeks, ARWR has reached a high of $42.48, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 31.77, while the 200-Day Moving Average is calculated to be 30.24.

Shares Statistics:

According to the various share statistics, ARWR traded on average about 1.65M shares per day over the past 3-months and 1.56M shares per day over the past 10 days. A total of 123.90M shares are outstanding, with a floating share count of 117.62M. Insiders hold about 5.06% of the company’s shares, while institutions hold 62.61% stake in the company. Shares short for ARWR as of Feb 29, 2024 were 8.84M with a Short Ratio of 5.37, compared to 7.72M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.13% and a Short% of Float of 8.37%.

Earnings Estimates

The company has 12 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of $3.27 and a low estimate of -$0.95, while EPS last year was $0.45. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.24 and low estimates of -$0.95.

Analysts are recommending an EPS of between -$1.26 and -$4.07 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$2.63, with 12 analysts recommending between -$1.46 and -$3.98.

Revenue Estimates

A total of 13 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $302M, while the lowest revenue estimate was $53.55M, resulting in an average revenue estimate of $139.03M. In the same quarter a year ago, actual revenue was $240.74M, down -42.20% from the average estimate.

Most Popular

[the_ad id="945"]